Personalized pancreatic cancer vaccines with pembrolizumab
Treatments studied
Part of Cancer clinical trials.
This early-phase trial tests a personalized cancer vaccine made from your tumor, along with pembrolizumab, to help the immune system attack advanced pancreatic cancer. It may be an option if your cancer has specific immune “targets” and if you meet several health, lab, and infection requirements.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18 or older and can sign consent and follow the study plan
- You have advanced pancreatic cancer (locally advanced, recurrent, or metastatic) confirmed by tumor testing, and standard treatment has failed or isn’t suitable
- Your tumor tissue must be enough for testing, and it must show at least one mutation that matches your immune type (HLA)
- You must be generally well enough (ECOG 0–1) and live for at least 4 months
- You must have measurable tumors on scans, and have adequate blood/organ function without certain medicines or transfusions around screening
- You must test negative for major viral infections and syphilis at baseline (CMV, EBV, HIV, HBV, HCV, syphilis)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized neoantigen vaccine given along with an anti-PD1 drug (pembrolizumab) and chemotherapy after surgery for pancreatic cancer. The goal is to see if this combination can help prevent the cancer from coming back.
This study tests a personalized vaccine made from your tumor's unique markers. It aims to help your immune system attack pancreatic cancer that has spread or returned.
This trial tests a personalized vaccine made from your own tumor's genetic information. The vaccine is given after surgery to try to train your immune system to fight any remaining cancer cells and reduce the chance of the cancer coming back.
This study tests a personalized vaccine made from your own tumor, combined with a drug that helps your immune system fight cancer cells. The goal is to see if this approach can help prevent your pancreatic cancer from coming back after surgery.
This trial tests a personalized mRNA vaccine combined with an immunotherapy drug (PD-1 inhibitor) to prevent pancreatic cancer from returning after surgery. It is for patients whose tumors have specific genetic features and who cannot have standard chemotherapy.
This trial tests a personalized vaccine (ODI-2001) that is made from your own tumor. It is given during a break from chemotherapy to see if it is safe and can help keep the cancer from growing.
Hear when a new Advanced Pancreatic Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.